Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS

Neurology

Volumn 46, Issue 2, 1996, Pages 379-384

  Filippi, M ^a,c   Yousry, T ^b   Campi, A ^a   Kandziora, C ^b   Colombo, B ^a   Voltz, R ^b   Martinelli, V ^a   Spuler, S ^b   Bressi, S ^a   Scotti, G ^a   Comi, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM PENTETATE;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN MAPPING; CLINICAL ARTICLE; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; DOSE RESPONSE; FEMALE; HUMAN; IMAGE ENHANCEMENT; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REPRODUCIBILITY;

EID: 9044234404     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.46.2.379     Document Type: Article

References (34)

1. Hawkins CP, Munro PMG, MacKenzie F, et al. Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers. Brain 1990;113:365-378.
2. Kermode AG, Thompson AJ, Tofts P, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain 1990;113:1477-1489.
3. Kermode AG, Tofts PS, Thompson AJ, et al. Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology 1990; 40:229-235
4. Hawkins CP, MacKenzie F, Tofts P, duBoulay EPGH, McDonald WI. Patterns of blood-brain barrier breakdown in inflammatory demyelination. Brain 1991;114:801-810.
5. Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993;34:661-669.
6. McDonald WI, Miller DH, Barnes D. The pathological evolution of multiple sclerosis. Neuropathol Appl Neurobiol 1992; 18:319-334.
7. Miller DH, Rudge P, Johnson G, et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988;111:927-939.
8. Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991;29:548-555.
9. Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry 1991;54:683-688.
10. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62.
11. Barkhof F, Scheltens P, Frenquin STFM, et al. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR Am J Roentgenol 1992;159:1041-1047.
12. Thompson AJ, Miller DH, Youl B, et al. Senal gadolinium-enhanced MRI in relapsing-remitting multiple sclerosis of varying disease duration. Neurology 1992;42:60-63.
13. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758-766.
14. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993;33:480-489.
15. Kidd D, Thompson AJ, Kendall BE, Miller DH, McDonald WI. Benign form of multiple sclerosis: MRI evidence for less frequent and less inflammatory disease activity. J Neurol Neurosurg Psychiatry 1994;57:1070-1072.
16. Khoury SJ, Guttmann CRG, Orav EJ, et al. Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden. Neurology 1994;44:2120-2124.
17. Miller DH, Barkhof F, Nauta JJP. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993;116:1077-1094.
18. Nauta JJP, Thompson AJ, Barkhof F, Miller DH. MR imaging in monitoring the treatment of MS patients: statistical power of parallel-groups and cross-over designs. J Neurol Sci 1994; 122:6-14.
19. McDonald WI, Miller DH, Thompson AJ. Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon-beta. Ann Neurol 1994;36:14-18.
20. Miller DH. Magnetic resonance in monitoring the treatment of multiple sclerosis. Ann Neurol 1994;36:S91-S94.
21. 1-weighted spin-echo images with use of magnetization transfer. Radiology 1994;36:62-67.
22. Haustein J, Laniado M, Niendorf HP, et al. Triple-dose versus standard-dose gadopentetate dimeglumine: a randomized study of 199 patients. Radiology 1993;186:855-860.
23. Yuh WTC, Fisher DJ, Mayr-Yuh NA, et al. Review of the use of high-dose gadoteridol in the magnetic resonance evaluation of central nervous system tumors. Invest Radiol 1992;27:539-544
24. Runge VM, Kirsch JE, Burke VI, et al. High-dose gadoteridol in MR imaging of intracranial neoplasms. JMRI 1992;2:9-18.
25. Runge VM, Kirsch JE, Thomas GS. High-dose applications of gadolinium chelates in magnetic resonance imaging. Magn Res Med 1991;22:358-363.
26. Wolansky LJ, Bardini JA, Cook SD, Zimmer AE, Sheffet A, Lee HJ. Triple-dose versus single-dose gadoteridol in multiple sclerosis patients. J Neuroimaging 1994;4:141-145.
27. Vinuela FV, Fox AJ, Debrun GM, Feasby TE, Ebers GC. New perspectives in computed tomography of multiple sclerosis. AJNR 1982;3:277-281.
28. Sears S, McCammon A, Bigelow R, Hayman LA. Maximizing the harvest of contrast enhancing lesions in multiple sclerosis. Neurology 1982;32:815-820.
29. Spiegel SM, Vinuela F, Fox AJ, Pelz DM. CT of multiple sclerosis: reassessment of delayed scanning with high doses of contrast material. AJR Am J Roentgenol 1985;145:497-500.
30. Tofts PS, Kermode AG. Measurements of the blood-brain barrier permeability and leakage space using dynamic MR imaging. I. Fundamental concepts. Magn Reson Med 1991;17:357-367.
31. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
32. Wicks DAG, Tofts PS, Miller DH, et al. Volume measurements of multiple sclerosis lesions with magnetic resonance images: a preliminary study. Neuroradiology 1992;34:475-479.
33. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994; 44:635-641.
34. Kilgore DP, Breger RK, Daniels DL, Pojunas KW, Williams AL, Haughton AM. Cranial tissues: normal MR appearance after intravenous injection of Gd-DTPA. Radiology 1986;160: 757-761.